Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - tibolone - טבליה - tibolone 2.5 mg - tibolone - tibolone - complaints resulting from the natural or artificial menopause. prevention of osteoporosis in estrogen deficiency states. treatment of estrogen deficiency symptoms in postmenopausal women.

Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin as sulfate - משחה - betamethasone as dipropionate 0.5 mg / 1 g; gentamicin as sulfate 1 mg / 1 g - topical treatment of dermatosis complicated by secondary infection caused by organisms sensitive to gentamicin

Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin (as sulfate) - קרם - gentamicin (as sulfate) 1 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, combinations with antibiotics - for the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.

Israel - hebreo - Ministry of Health

תעשיות תמרוקים שיק 1989 בעמ - ריכוך השיער

Israel - hebreo - Ministry of Health

תעשיות תמרוקים שיק 1989 בעמ - עיצוב לשיער

Israel - hebreo - Ministry of Health

תעשיות תמרוקים שיק 1989 בעמ - חפיפת שיער

Israel - hebreo - Ministry of Health

בי.פור.יו בעמ - לחות לעור

Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - hydrochlorothiazide; losartan potassium - טבליה - losartan potassium 50 mg; hydrochlorothiazide 12.50 mg - losartan and diuretics - losartan and diuretics - ocsaar plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hyperfension adn left ventricular hypertrophy.

Israel - hebreo - Ministry of Health

organon pharma israel ltd., israel - ezetimibe - טבליה - ezetimibe 10 mg - ezetimibe - ezetimibe - primary hypercholesterolemia: ezetrol administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetrol administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezetrol are indicated for use in patients with homozygous familial sitosterolemia.